Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
45 hedge funds and large institutions have $4.23M invested in Infinity Pharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 10 closing their positions.
525% more call options, than puts
Call options by funds: $25K | Put options by funds: $4K
37% more capital invested
Capital invested by funds: $3.1M → $4.23M (+$1.13M)
15% less funds holding
Funds holding: 53 → 45 (-8)
47% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 15
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
+$208K |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
+$52.1K |
| 3 |
Renaissance Technologies
New York
|
+$21.4K |
| 4 |
EWM
Evercore Wealth Management
New York
|
+$12.6K |
| 5 |
WIM
Wittenberg Investment Management
Carlisle,
Massachusetts
|
+$9.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$68.3K |
| 2 |
VF
Virtu Financial
New York
|
-$24.7K |
| 3 |
Millennium Management
New York
|
-$21K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ASN
51
Advisory Services Network
Atlanta,
Georgia
| – | -$128 | -800 | Closed |
|
|
TWA
52
TCI Wealth Advisors
Tucson,
Arizona
| – | -$32 | -200 | Closed |
|
|
QC
53
Quent Capital
New York
| – | -$15 | -94 | Closed |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$11 | +61 | +7% |
|
INFI Hedge Fund Activity: Q2 2023 in Review
45 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q2 2023, worth a combined $4.23M — up 37% from $3.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of INFI and 2 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 8 added.
The largest buyer was Mariner, opening a new position worth an estimated $208K. The largest seller was Citadel Advisors, exiting entirely with an estimated $68.3K sold.
- 45 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q2 2023, down from 53 in Q1 2023.
- Funds reported $4.23M of Infinity Pharmaceuticals, Inc. stock for Q2 2023, up 37% quarter-over-quarter.
- 2 funds opened new Infinity Pharmaceuticals, Inc. positions in Q2 2023 and 10 closed out, a net change of -8 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q2 2023 was Mariner, an estimated $208K added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q2 2023 was Citadel Advisors, an estimated $68.3K sold.
Based on aggregated 13F filings for Q2 2023.